Mismatch repair/microsatellite instability (MMR/MSI) testing practices among United States physicians treating patients (pts) with advanced/metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Eriksson, Jennifer
Amonkar, Mayur
Thomson, Gemma
Lambert, Jeremy
Malmenas, Mia
Chase, Monica
Sun, Lucy
Kollmar, Linda Grossman
Vichnin, Michelle
机构：
[1] ICON Plc, Commercialisat & Outcomes, Stockholm, Sweden
[2] Merck & Co Inc, N Wales, PA USA
[3] ICON Plc, London, England
[4] Mapi, Lyon, France
[5] ICON Plc, Stockholm, Sweden
[6] ICON Plc, Commercialisat & Outcomes, Boston, MA USA
[7] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
533
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis Michel
    Garcia-Carbonero, Rocio
    Alcaide, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna C.
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David R.
    Marinello, Patricia
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Nuclear translocation of ATG5 induces DNA mismatch repair deficiency (MMR-D)/microsatellite instability (MSI) via interacting with Mis18α in colorectal cancer
    Sun, Shi-Yue
    Hu, Xue-Tao
    Yu, Xin-Feng
    Zhang, Yue-Ying
    Liu, Xiao-Hui
    Liu, Yuan-Hang
    Wu, Shu-Hua
    Li, Yang-Yang
    Cui, Shu-Xiang
    Qu, Xian-Jun
    BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (11) : 2351 - 2369
  • [43] SYSTEMATIC AND STRUCTURED REVIEWS OF THE DISEASE BURDEN IN PATIENTS WITH MICROSATELLITE INSTABILITY HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) COLORECTAL CANCER (CRC)
    Amonkar, M.
    Chase, M.
    Takyar, J.
    Sharma, S.
    VALUE IN HEALTH, 2021, 24 : S24 - S24
  • [44] Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States
    Kelkar, Sneha S.
    Prabhu, Vimalanand S.
    Zhang, Jingchuan
    Corman, Shelby
    Macahilig, Cynthia
    Rusibamayila, Nifasha
    Odak, Shardul
    Duska, Linda R.
    GYNECOLOGIC ONCOLOGY REPORTS, 2022, 42
  • [45] Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing
    Hissong, Erika
    Crowe, Elizabeth P.
    Yantiss, Rhonda K.
    Chen, Yao-Tseng
    MODERN PATHOLOGY, 2018, 31 (11) : 1756 - 1766
  • [46] Pembrolizumab (pembro) for previously treated, microsatellite instabilityehigh (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
    Le, D. T.
    Diaz, L.
    Kim, T. W.
    Van Cutsem, E.
    Geva, R.
    Jager, D.
    Hara, H.
    Burge, M.
    O'Neil, B.
    Kavan, P.
    Yoshino, T.
    Guimbaud, R.
    Taniguchi, H.
    Elez, E.
    Al-Batran, S-E.
    Boland, P.
    Cui, Y.
    Leconte, P.
    Marinello, P.
    Andre, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S550 - S550
  • [47] Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study
    Overman, M. J.
    Kopetz, S.
    Lonardi, S.
    McDermott, R.
    Leone, F.
    Leach, J.
    Lenz, H-J.
    Hendlisz, A.
    Morse, M.
    Garcia-Alfonso, P.
    Desai, J.
    Hill, A.
    Moss, R. A.
    Goldberg, M. V.
    Lin, C-S.
    Tang, H.
    Andre, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.
    Overman, Michael J.
    Lonardi, Sara
    Leone, Francesco
    McDermott, Raymond S.
    Morse, Michael A.
    Wong, Ka Yeung Mark
    Neyns, Bart
    Leach, Joseph L.
    Alfonso, Pilar Garcia
    Lee, James J.
    Hill, Andrew
    Lenz, Heinz-Josef
    Desai, Jayesh
    Moss, Rebecca A.
    Cao, Z. Alexander
    Ledeine, Jean-Marie
    Tang, Hao
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [50] Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
    Colle, Raphael
    Radzik, Anna
    Cohen, Romain
    Pellat, Anna
    Lopez-Tabada, Daniel
    Cachanado, Marine
    Duval, Alex
    Svrcek, Magali
    Menu, Yves
    Andre, Thierry
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 9 - 16
12345